JNJ-26489112

Investigational

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C9H11ClN2O4S
Molecular Weight	278.713
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

SMILES

NS(=O)(=O)NC[C@H]1COC2=C(O1)C=CC(Cl)=C2

InChI

InChIKey=KXSAIQPPGSSNKX-ZETCQYMHSA-N

InChI=1S/C9H11ClN2O4S/c10-6-1-2-8-9(3-6)15-5-7(16-8)4-12-17(11,13)14/h1-3,7,12H,4-5H2,(H2,11,13,14)/t7-/m0/s1

HIDE SMILES / InChI

Molecular Formula	C9H11ClN2O4S
Molecular Weight	278.713
Charge	0
Count	MOL RATIO 1 MOL RATIO (average)

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	1 / 1
E/Z Centers	0
Optical Activity	UNSPECIFIED

Approval Year

Substance Class	Chemical
Record UNII	G1TI012DLT
Record Status	`Validated (UNII)`
Record Version

Show entries

Name

Type

Language

JNJ-26489112

Code

English

SULFAMIDE, N-(((2S)-6-CHLORO-2,3-DIHYDRO-1,4-BENZODIOXIN-2-YL)METHYL)-

Systematic Name

English

Showing 1 to 2 of 2 entries

Previous1Next

Show entries

Code System

Code

Type

Description

PUBCHEM

11616111

PRIMARY

CAS

871824-55-4

PRIMARY

WIKIPEDIA

JNJ-26489112

PRIMARY

JNJ-26489112 is an anticonvulsant drug being developed by Johnson & Johnson for the treatment of epilepsy. JNJ-26489112 was designed as a successor to topiramate. It is expected to have fewer side effects than topiramate because it lacks activity against carbonic anhydrase. JNJ-26489112 is also being studied as a treatment for major depressive disorder.

DRUG BANK

DB15203

PRIMARY

EPA CompTox

DTXSID601031470

PRIMARY

Showing 1 to 5 of 6 entries

Previous1 2Next

Show entries

Related Record

Type

Details


					G1TI012DLT

JNJ-26489112

ACTIVE MOIETY

Comments:

Developer: Janssen Research & Development; Class: Antidepressant, Antiepileptic drug; Highest Development Phase: Discontinued for Epilepsy, Major depressive disorder; Most Recent Events: 01 Oct 2013 Discontinued - Phase-I for Epilepsy (in volunteers) in Belgium (PO), 01 Oct 2013 Discontinued - Phase-II for Epilepsy in USA (PO), 12 Mar 2012 Discontinued - Phase-II for Depressive disorders in USA (PO)


					G1TI012DLT

JNJ-26489112

ACTIVE MOIETY

Comments:

RESULTS: The majority of patients showed a positive response on day 2 following JNJ-26489112 administration: 3/4 patients (1000 mg dose), 3/4 patients (2000 mg dose), and 2/3 patients (3000 mg). There was an apparent dose-dependent effect observed in patients who exhibited complete suppression of the SPR: 0/4 patients (1000 mg dose), 1/4 patient (2000 mg dose), and 2/3 patients (3000 mg dose). The median tmax of JNJ-26489112 (range: 3.73-5.04 h) in plasma was similar across all 3 dose groups and plasma exposure of JNJ-26489112 increased proportionally with dose approximate mean Cmax of 16, 28, and 42 .MU.g/mL for the 1000-, 2000-, and 3000 mg cohorts, respectively. Concentrations of other AEDs did not appear to be affected by co-administration of JNJ-26489112. JNJ-26489112 was generally well-tolerated with the most frequent adverse events (>10%) reported being mild headache, dizziness, and nausea.

Showing 1 to 2 of 2 entries

Previous1Next